Application of Tangning Tongluo capsule, a new diabetes drug of Guizhou bailing, to medical institutions

August 24, bailing, Guizhou According to the investor interaction platform, Tangning Tongluo capsule, the company's new diabetes drug, is currently applying for the preparation of medical institutions The company's relevant personnel are in charge of ensuring the progress of each department Due to the review of the preparation of medical institutions and the acceptance of specialized hospitals, relevant departments also provide strong support, but we still need to wait patiently Guizhou bailing announced on July 16 that the effectiveness of Tangning Tongluo Capsule to be developed by the company in the treatment of type 2 diabetes mellitus with deficiency of both qi and Yin has been confirmed The clinical effect of traditional Chinese medicine is good, which can significantly reduce the syndrome score of traditional Chinese medicine, significantly reduce fasting blood sugar, blood sugar and glycosylated hemoglobin 2 hours after meal, greatly improve the main symptoms and signs of patients and diabetes complicated with microangiopathy (visual matter Fuzzy), significantly better than placebo In terms of safety, the test drug has less adverse reactions and light reactions, which is worth clinical application Guizhou bailing is one of the largest enterprises in the R & D and production of Miao medicine in China The number of Miao medicine products with invention patents and the sales volume of OTC Miao medicine products rank first in China, and have the ability to integrate Miao medicine industry and related resources.